Patients with severe lupus nephritis who have both diffuse proliferative (class IV) and membranous (class V) lesions on biopsy can be refractory to current monotherapy treatments. Bao et al.

the interpretation was that the low albumin and proteinuria likely represented nephrotic syndrome and that this argued for the possibility of class V lupus nephritis or the membranous lupus lesion.

[1] In previous years, randomized, controlled trials (RCTs) at the NIH and other institutions, mainly involving patients with severe lupus nephritis, have demonstrated the superiority of the ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Systemic lupus erythematosus is a complex autoimmune disorder affecting multiple organ systems. Glomerulonephritis leading to severe proteinuria, chronic renal failure and end-stage renal disease ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

We also conduct clinical trials that involve treatment of kidney diseases due to multiple inflammatory causes, including lupus, focal segmental glomerulonephritis, membranous glomerulonephritis, ...